Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

BioRock Ventures

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 6
Average round size
info
The average size of a deal this fund participated in
$5M
Portfolio companies 5
Rounds per year 1.20
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of BioRock Ventures:
Typical Co-investors
BioRock Ventures is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after BioRock Ventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
A-Z Beteiligungen Cologne, Germany, Nordrhein-Westfalen
Aquacopia Venture Partners New York, New York, United States
Dundon Capital Partners Dallas, Texas, United States
Emergic Ventures India, Maharashtra, Mumbai
Fierce Founders Accelerator -
Folens -
Infront Sports & Media Switzerland, Zug, Zug
J. Hunt Holdings United States, Vienna, Virginia
JSM Capital British Columbia, Canada, Vancouver
Kaufman Financial Group Connecticut, Farmington, United States
LORE Associates Pennsylvania, United States, Wayne
NAC Japan, Tokyo
PNC Business Credit Haywards Heath, United Kingdom, West Sussex
Relational Investors LLC. California, San Diego, United States
SourceSquared Management Massachusetts, United States, Woburn
Stonehenge Growth Equity Florida, Tampa, United States
Three Fish Capital California, San Francisco, United States
WRAP Cherwell, England, United Kingdom
Zing Capital United States, Vancouver, Washington

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Celldom, Inc

Biotechnology
Genetics
Life Science
01 Jan 2021 Durham, North Carolina, United States

Primmune Therapeutics

Biotechnology
Health Care
$27M27 Oct 2020 San Diego, California, United States

Primmune Therapeutics

Biotechnology
Health Care
$7M02 Mar 2020 San Diego, California, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent BioRock Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 6
Average round size 5M
Rounds per year 1.20
Peak activity year 2020
Lead investments 0
Follow on index 0.17
Group Appearance index 0.50

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Celldom, Inc

Biotechnology
Genetics
Life Science
01 Jan 2021 Durham, North Carolina, United States

Primmune Therapeutics

Biotechnology
Health Care
$27M27 Oct 2020 San Diego, California, United States

Primmune Therapeutics

Biotechnology
Health Care
$7M02 Mar 2020 San Diego, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: